Navigation Links
Advance in Program for Development of Non-Intravenous Therapy for Hemophilia

Baxter AG and Jerini AG in Germany have announced progress in their collaborative research program to develop a non-intravenous therapy// for the treatment of hemophilia.

Extensive in vitro and in vivo analysis has identified several synthetic lead molecules with promising pharmacological properties.

"Using our proprietary technology platform, we continue to make important progress in our collaboration with Baxter, the leader in hemophilia therapy," said Jens Schneider-Mergener, Jerini AG's chief executive officer. "We are encouraged by the identification of these molecules and the evaluation of the potential to treat hemophilia using a non-intravenous therapy with molecules that can be synthetically produced."

Scientists from Baxter and Jerini used proprietary tailored screening and analysis methods to design molecules with the ability to promote the coagulation of blood. Following further analysis, several principal molecules that showed promising activity in mouse models of hemophilia were selected for further development.

Because blood-clotting proteins are large, relatively unstable molecules, current hemophilia therapies can only be administered intravenously, which is an invasive and technically demanding procedure. It is presently not possible to administer these molecules by non-intravenous routes because of poor distribution or rapid inactivation of the molecule in the body. Therefore, potential non-intravenous therapy must be able to reach its target site quickly and effectively without being inactivated in the process.

"We are very pleased by the progress to date in this collaboration with Jerini," said Friedrich Scheiflinger, PhD, senior director of discovery research and technical assessment for Baxter's BioScience business. "This partnership builds on Baxter's rich history of innovation in hemophilia therapy development and underscores our long-term commitment to improving therapies for people wi
'"/>




Page: 1 2 3

Related medicine news :

1. Advances in Treatment of Cataracts
2. Advanced STD programs required
3. Hope For Patients With Advanced Breast Cancer
4. Advances In Stem Cells Research
5. Breast Cancer Advance
6. Canadian Lung Cancer Study Lauded As Major Advance in Cancer Fight
7. Speedier Access To Advances In Breast Cancer Sought For Patients
8. HIV Vaccine Field Trials In Advanced Stage
9. Advance Funeral For AIDS-infected South African
10. New Screening Techniques to Lead Advances In Pain Therapy
11. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
Post Your Comments:
(Date:7/29/2014)... Roanoke, Virginia (PRWEB) July 29, 2014 ... a featured lecturer at the Florida Chiropractic Association (FCA) ... and Their Effects on the Kinetic Chain Changes on ... Florida. Greenawalt’s talk is focusing on the positive impact ... on conditions such as low back pain, plantar fasciitis, ...
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 PharmaSphere: ... Biosimilars Market report is an essential source of ... Using detailed company data, financial analysis, corporate strategy, ... of the current and future growth drivers of ... regulatory frameworks under which biosimilars are currently reviewed ...
(Date:7/29/2014)... 29, 2014 1WorldSync announces B. ... healthcare suppliers will utilize the Global Data Synchronization ... network to share product information with the U.S. ... partners across their global supply chain. Holger Clobes, ... B. Braun: "B. Braun serves customers in 61 ...
(Date:7/29/2014)... Catalent Pharma Solutions, the global leader ... for pharmaceutical, biologic, and consumer health products, today ... US Platform Leader of Pharmaceutical Softgels, will present ... Formulations using Soft Capsule Delivery Systems” at the ... of Drug Delivery Systems (30-31 July 2014, Tokyo, ...
Breaking Medicine News(10 mins):Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... pre-packed Camembert to shrink-wrapped meat loaf choosing the ... industry. Companies need to protect food products from oxygen, ... fresh for as long as possible. Transparent multilayer films, ... used to protect food from contamination. To minimize the ...
... Tuning in to tune out may be just what,s ... at the Duke Cancer Institute. The Duke team found ... pain and anxiety of the often uncomfortable procedure. The ... points to a simple and inexpensive way to help an ...
... This release is available in Spanish . ... gather and characterise in detail 110 cases of cardiac rupture ... Hospital de Cruces, near Bilbao. It is one of the ... most serious complication of acute myocardial infarction; it is not ...
... new study by NYU Langone Medical Center researchers identified ... of fat and cholesterol that hardens into plaque and ... Immunology on January 8, 2012, explains why cholesterol-laden, ... plaques. "We have discovered that macrophages that accumulate ...
... , SUNDAY, Jan. 8 (HealthDay News) -- People ... genes as those in the general population, but they may ... so long, researchers report. The team of U.S. scientists ... with only one per 5 million people in developed nations. ...
... at the Translational Genomics Research Institute (TGen) have begun ... to lung cancer in never-smokers a first step ... starting point. We certainly have a lot of pathways ... very interested in confirming and looking at in larger ...
Cached Medicine News:Health News:Film coatings made from whey 2Health News:Film coatings made from whey 3Health News:Headphone music eases anxiety during prostate biopsies 2Health News:Keys for detecting cardiac rupture 2Health News:Keys for detecting cardiac rupture 3Health News:Researchers discover new culprit in atherosclerosis 2Health News:Why Some People Live to 110 2Health News:TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers 2
(Date:7/29/2014)... 29, 2014 Cynosure, Inc. (Nasdaq: ... and light-based aesthetic treatment systems for high-volume applications, today ... 30, 2014. Second-quarter 2014 financial results incorporate the acquisition ... 24, 2013. Second-Quarter 2014 Financial ... to $72.6 million , Non-GAAP net income of ...
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation ... and Pressure Area Care sectors, announces that it is appealing ... in Germany that found ... Apex notes that it has initiated invalidity challenges against various ... efforts in counterattacking against trivial and junk patents. ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Apex Continues Fighting Against Patents to Free Up Competition 2
... initiate Phase 1 trial of AKIi-5 as the first ... ... Aug. 2 Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company ... today the,presentation of positive results from preclinical efficacy studies ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
... is an excellent choice to treat DeQuervain's ... joint, basal joint arthritis, advanced carpal tunnel ... thumb and wrist. Distal palmar crease ... and full finger dexterity. Constructed from ...
... Wrist Flex is a custom wrist orthotic designed to ... to the patient's maximum range-of-motion. , ,Indications: , ... TFCC tear-triangular fibrocartilage complex , Coles fracture ... , Partial tendon rupture , ORIF ...
The Contoured Wrist/Forearm Support provides comfort for post-surgical immobilization, post-fracture casting, and wrist sprains and strains....
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
Medicine Products: